Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB

You may also be interested in...



Going Solo: Non-Combination TB Drugs In Development

FDA Developing Guidance On Rational Development Of Combined Novel Drugs

FDA is developing guidances -both in general and for specific therapeutic areas - for co-development of investigational drugs intended to be used in combination, and the move is indeed timely.

FDA Developing Guidance On Rational Development Of Combined Novel Drugs

 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel